A potential breakthrough in Ewing sarcoma has been uncovered at the Weizmann Institute in Israel, pioneered by Professor Yosef Yarden and Dr Swati Srivastava.
Ewing sarcoma is a rare cancer that forms in bones and soft tissues which is mainly found in people from the ages of 10 to 20. It is the second most commonly diagnosed primary bone cancer in young people.
Dr Srivastava and her team have discovered molecular interactions underlying Ewing sarcomas and proposed potential treatment, which has shown promise in a study on mice.
These findings open the door to new treatment options for this cancer, and if confirmed in human patients may offer new hope to youngsters with this disease, especially when the sarcoma has spread beyond the bone.
Dr Srivastava said: “Our findings provide the basis for a personalised approach to the treatment of Ewing sarcoma. The fact that the study made use of drugs that have already been approved for other uses should facilitate the implementation of this approach”.
